Clinical symptoms of SARS-CoV-2 breakthrough infection during the Omicron period in relation to baseline immune status and booster vaccination-A prospective multicentre cohort of health professionals (SURPRISE study).
Philipp P KohlerBaharak Babouee FlurySabine GüsewellThomas EggerOnicio LealAngela BrucherEva LemmenmeierDorette Meier KleebJ Carsten MöllerManuela OrtnerPhilip RiederMarkus RuettiHans-Ruedi SchmidReto StockerDanielle Vuichard-GysinOliver SpeerBenedikt WiggliUlrike BesoldAllison J McGeerLorenz RischAndrée FriedlMatthias SchlegelPietro VernazzaChristian R KahlertStefan P Kusternull nullPublished in: Influenza and other respiratory viruses (2023)
The effects of different types of pre-existing immunity on the frequency of clinical symptoms caused by the SARS-CoV-2 breakthrough infection were prospectively assessed in healthcare workers during the Omicron period. Among 518 participants, hybrid immunity was associated with symptom reduction for dizziness, muscle or limb pain and headache as compared to vaccination only. Moreover, the frequencies of dizziness, cough and muscle or limb pain were lower in participants who had received a booster vaccine dose. Thus, hybrid immunity appeared to be superior in preventing specific symptoms during breakthrough infection compared to vaccination alone. A booster vaccine dose conferred additional symptom reduction.